ILF / WHO / CHAI webinar
REPORT BACK ON PADO 3 REVIEW

Conference call through WebEx

Monday, 5 February 2018

Option 1: 05:30-06:30 EST / 11:30-12:30 CET / 16:00-17:00 IST
Option 2: 11:00-12:00 EST / 17:00-18:00 CET / 21:30-22:30 IST
Key considerations: Compliance with competition rules

What to avoid

• Do not discuss with other participants competitively sensitive information on anything relating to topics such as prices, discounts, margins, price-related contractual terms or territorial protection.
• Do not exchange information on costs, capacity, business plans or commercial strategy. The only exception is for industry data that are publicly available via data services, such as interest rates.
• Do not exchange individualized information on output plans.
• Do not engage in conduct that could have the effect of restricting competition by excluding actual or potential competitors from the market or preventing them from competing effectively.
• Do not discuss matters relating to your company’s marketing plans, design, production or distribution.
• Do not share with other participants any other competitively sensitive or confidential information.

What to do

• Do report to the IAS any discussion or conduct that you suspect might violate these guidelines, and keep a copy of such correspondence.
• Do leave any discussion that you feel might infringe these guidelines, and ask for your leaving to be recorded in the minutes.
• Do refuse any commercially sensitive or confidential information you might be offered. If you receive such information, return them immediately, emphasizing that you do not want to have access to them. Keep a copy of such correspondence.
• Do remember that you are responsible for your own compliance with these guidelines.
Today’s webinar objectives

• Summarize the key outcomes of the PADO review of its list of priority paediatric ARV formulations

• Present some of the next steps for further prioritizing specific drug formulations

• Discuss some of the most pressing evidence gaps

• Allow industry an opportunity to ask questions and provide feedback
Today’s agenda

5 minutes  Welcome and introduction
Sébastien Morin (IAS)

15 minutes  PADO 3 Implementation:
Progress and remaining hurdles in a changing environment
Martina Penazzato (WHO)

10 minutes  PADO 3 Implementation:
Internal prioritization to maximize impact
Melynda Watkins (CHAI)

10 minutes  Remaining evidence gaps: the PADO research agenda
Marissa Vicari (IAS)

15 minutes  Q&A
Facilitated by Sébastien Morin (IAS)

5 minutes  Closing remarks
Sébastien Morin (IAS)
Prioritizing paediatric formulation development

The Global Accelerator for Paediatric Formulations (GAP-f)

Coordination of upstream processes
- Prioritization
- Research
- Development
- Regulatory approval (SRAs)

Coordination of downstream processes
- Procurement
- Regulatory approval (NRAs)
- Introduction
- Pharmacovigilance

Accelerating priority paediatric drug formulation development and uptake

PADO
(Paediatric ARV Drug Optimization group)

More information on GAP-f [here](#).
Prioritizing paediatric formulation development

Access the paper [here](#).

Access the report [here](#).
## Today’s agenda

<table>
<thead>
<tr>
<th>Duration</th>
<th>Topic</th>
<th>Presenter/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 minutes</td>
<td>Welcome and introduction</td>
<td>Sébastien Morin (IAS)</td>
</tr>
<tr>
<td>15 minutes</td>
<td>PADO 3 Implementation: Progress and remaining hurdles in a changing environment</td>
<td>Martina Penazzato (WHO)</td>
</tr>
<tr>
<td>10 minutes</td>
<td>Internal prioritization to maximize impact</td>
<td>Melynda Watkins (CHAI)</td>
</tr>
<tr>
<td>10 minutes</td>
<td>Remaining evidence gaps: the PADO research agenda</td>
<td>Marissa Vicari (IAS)</td>
</tr>
<tr>
<td>15 minutes</td>
<td>Q&amp;A</td>
<td>Facilitated by Sébastien Morin (IAS)</td>
</tr>
<tr>
<td>5 minutes</td>
<td>Closing remarks</td>
<td>Sébastien Morin (IAS)</td>
</tr>
</tbody>
</table>
THANK YOU